Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Defence Therapeutics Inc., CA24463V1013

Defence Therapeutics Inc., CA24463V1013

31.08.2021 - 08:33:10


Size, Share, Price, Trends, Growth, Analysis, Report and Forecast 2021-2026", the global hydrogel market is an effervescence field with a revenue of $23.6 billion in 2020 and an expected CAGR of 7.0% over the next five years to reach $35.5 billion in 2026. The diverse used application of hydrogel such as Medical Fields, Industrial Fields, Consumer Goods will drive the Hydrogel market.

Key players in the biotech/pharma industry are Alcon (Novartis AG), Johnson & Johnson Services Inc. and 3M Company.

About Defence: Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information: Sebastien Plouffe, President, CEO and Director P: (514) 947-2272Splouffe@defencetherapeutics.comwww.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

31.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Defence Therapeutics Inc. 1680 - 200 Burrard St V6C3L6 Vancouver

Canada E-mail: info@defencetherapeutics.com Internet: https://defencetherapeutics.com ISIN: CA24463V1013 WKN: A3CN14 Listed: Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto EQS News ID: 1229908 ? End of News DGAP News Service


@ dgap.de